Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study

被引:30
作者
Wilson, Gregory C. [1 ]
Maithel, Shishir K. [2 ]
Bentrem, David [6 ]
Abbott, Daniel E. [7 ]
Weber, Sharon [7 ]
Cho, Clifford [7 ]
Martin, Robert C. G. [3 ]
Scoggins, Charles R. [3 ]
Kim, Hong Jin [4 ]
Merchant, Nipun B. [5 ]
Kooby, David A. [2 ]
Edwards, Michael J. [1 ]
Ahmad, Syed A. [1 ]
机构
[1] Univ Cincinnati, Med Ctr, Dept Surg, Div Surg Oncol, Cincinnati, OH 45267 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Louisville, Louisville, KY 40292 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Univ Miami, Miami, FL USA
[6] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA
[7] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
关键词
INTERNATIONAL-CONSENSUS-GUIDELINES; CYSTIC NEOPLASMS; TREATED PATIENTS; SENDAI; ASSOCIATION; EXPERIENCE; RISK; SIZE; IPMN;
D O I
10.1016/j.jamcollsurg.2016.12.031
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Controversy persists regarding the management of patients with intraductal papillary mucinous neoplasms (IPMN). International consensus guidelines stratify patients into high-risk, worrisome, and low risk categories. STUDY DESIGN: The medical records of 7 institutions were reviewed for patients who underwent surgical management of IPMN between 2000 and 2015. RESULTS: There were 324 patients included in the analysis; 60.4% of patients had main-duct/mixed type, and 39.7% had branch-duct IPMN. The median cyst size was 2.65 cm, invasive cancer (IC) or high-grade dysplasia (HGD) was present in 42% (n = 136); 68.9% of patients with high-risk, 40.0% of patients with worrisome, and 24.6% of patients with low risk features exhibited HGD/IC. Multivariate analysis demonstrated that only 1 of 3 high-risk features and 2 of 7 worrisome features predicted the presence ofHGD/IC. Positive predictive values for HGD/IC in patients with obstructive jaundice and lymphadenopathy were 0.83 (95% CI 0.65 to 0.94) and 0.69 (95% CI 0.39 to 0.91), respectively. In the absence of high-risk features, HGD/IC was still present in 57.4% of patients with 2 or more worrisome features. Regression analysis demonstrated that each additional worrisome factor present was additive in predicting HGD/IC in a linear fashion (odds ratio 1.39; 95% CI 1.08 to 1.80; p < 0.01). CONCLUSIONS: These data demonstrate that the current consensus guidelines for surgical resection of IPMN may not adequately stratify and identify patients at risk for having HGD or invasive cancer. Patients with multiple worrisome features, in the absence of high-risk factors, should be considered for resection. (C) 2017 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:461 / 469
页数:9
相关论文
共 50 条
  • [1] Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas
    Hirono, Seiko
    Yamaue, Hiroki
    SURGERY TODAY, 2020, 50 (01) : 50 - 55
  • [2] Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms? A Multi-institutional Study
    Dhar, Vikrom K.
    Merchant, Nipun B.
    Patel, Sameer H.
    Edwards, Michael J.
    Wima, Koffi
    Imbus, Joseph
    Abbott, Daniel E.
    Weber, Sharon M.
    Louie, Raphael
    Kim, Hong J.
    Martin, Robert C. G.
    Scoggins, Charles R.
    Bentrem, David J.
    LeCompte, Michael T.
    Idrees, Kamran
    Lopez-Aguiar, Alexandra G.
    Maithel, Shishir K.
    Kooby, David A.
    Franco, Daniel A.
    Yakoub, Danny
    Ahmad, Syed A.
    ANNALS OF SURGERY, 2018, 268 (03) : 469 - 478
  • [3] The management of intraductal papillary mucinous neoplasms of the pancreas
    Pollini, Tommaso
    Andrianello, Stefano
    Caravati, Andrea
    Perri, Giampaolo
    Malleo, Giuseppe
    Paiella, Salvatore
    Marchegiani, Giovanni
    Salvia, Roberto
    MINERVA CHIRURGICA, 2019, 74 (05) : 414 - 421
  • [4] Surgical therapy of intraductal papillary mucinous neoplasms of the pancreas
    Fritz, S.
    Buechler, M. W.
    Werner, J.
    CHIRURG, 2012, 83 (02): : 130 - 135
  • [5] Uptodate in the assessment and management of intraductal papillary mucinous neoplasms of the pancreas
    Pagliari, D.
    Saviano, A.
    Serricchio, M. L.
    Dal Lago, A. A.
    Brizi, M. G.
    Lanza, F.
    Manfredi, R.
    Gasbarrini, A.
    Attili, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (12) : 2858 - 2874
  • [6] Management of intraductal papillary mucinous neoplasms of the pancreas
    Perez-Johnston, R.
    Lin J, D.
    Carlos, C. Fernandez-Del Castillo
    Sahani, D.
    MINERVA CHIRURGICA, 2009, 64 (05) : 477 - 487
  • [7] Imaging patterns of intraductal papillary mucinous neoplasms of the pancreas: An illustrated discussion of the International Consensus Guidelines for the Management of IPMN
    Campbell, Naomi M.
    Katz, Seth S.
    Escalon, Joanna G.
    Do, Richard K.
    ABDOMINAL IMAGING, 2015, 40 (03): : 663 - 677
  • [8] Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas
    Seiko Hirono
    Hiroki Yamaue
    Surgery Today, 2020, 50 : 50 - 55
  • [9] Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach? Results from a Multi-institutional Study
    Pulvirenti, Alessandra
    Margonis, Georgios A.
    Morales-Oyarvide, Vicente
    McIntyre, Caitlin A.
    Lawrence, Sharon A.
    Goldman, Debra A.
    Gonen, Mithat
    Weiss, Matthew J.
    Ferrone, Cristina R.
    He, Jin
    Brennan, Murray F.
    Cameron, John L.
    Lillemoe, Keith D.
    Kingham, T. Peter
    Balachandran, Vinod
    Qadan, Motaz
    D'Angelica, Michael, I
    Jarnagin, William R.
    Wolfgang, Christopher L.
    Fernandez-del Castillo, Carlos
    Allen, Peter J.
    ANNALS OF SURGERY, 2021, 274 (06) : E980 - E987
  • [10] Intraductal papillary mucinous neoplasms of the pancreas: A surgical perspective
    Sakorafas, George H.
    Sarr, Michael G.
    van de Velde, Cornelis J. H.
    Peros, George
    SURGICAL ONCOLOGY-OXFORD, 2005, 14 (04): : 155 - 178